1-methyltryptophan has been researched along with Colorectal Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, T; Li, X; Lin, B; Liu, C; Luo, S; Shi, J; Wang, S; Zhang, X; Zheng, T; Zhou, M | 1 |
1 other study(ies) available for 1-methyltryptophan and Colorectal Neoplasms
| Article | Year |
|---|---|
STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinogenesis; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Disease Models, Animal; Disease Progression; Female; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Membrane Proteins; Mice; Mice, Inbred C57BL; Myeloid-Derived Suppressor Cells; Neoplasm Transplantation; Programmed Cell Death 1 Receptor; Tryptophan | 2021 |